RxDoctor Payments Data

Ron Golan, MD

Urology · Santa Barbara, CANPI 1861835852

Payments from drug & device makers

$5,602in general payments, 2019–2025

Across 114 payments — averaging $49.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$1K
  • Boston Scientific$836
  • Teleflex LLC$467
  • Histosonics, Inc.$328
  • Olympus America Inc.$281
  • AbbVie$269
  • plus $2K from 20 others

What the payments were for

  • Consulting fees$2665%
  • Speaking & faculty fees$1062%
  • Travel & lodging$3907%
  • Food & beverage$4,81586%
  • Gifts$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,602 in reported general payments places this provider in the 65th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$414,202
Medicare patients
865
Services billed
9,561

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron149$137,571
GemtesaVibegron110$109,856
Mirabegron ErMirabegron12$9,972
Tamsulosin Hcl493$6,616
Finasteride319$4,213
Estradiol57$4,182
Tadalafil18$2,612
Methenamine Hippurate20$2,165
Potassium Citrate ErPotassium Citrate17$2,125
Desmopressin Acetate12$1,589
Silodosin12$1,337
Oxybutynin Chloride ErOxybutynin Chloride43$1,149
Dutasteride18$713
Alfuzosin Hcl ErAlfuzosin Hcl34$654
Sildenafil Citrate12$391

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$142$109,856110 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,324 urology providers in California.

Other urology in Santa Barbara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →